- Home
- LNN vs VRDN Comparison
LNN vs VRDN Comparison
Compare LNN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNN
- VRDN
- Stock Information
- Founded
- LNN 1954
- VRDN 2006
- Country
- LNN United States
- VRDN United States
- Employees
- LNN N/A
- VRDN N/A
- Industry
- LNN Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- LNN Industrials
- VRDN Health Care
- Exchange
- LNN Nasdaq
- VRDN Nasdaq
- Market Cap
- LNN 1.5B
- VRDN 1.5B
- IPO Year
- LNN 1988
- VRDN N/A
- Fundamental
- Price
- LNN $141.10
- VRDN $19.62
- Analyst Decision
- LNN Hold
- VRDN Strong Buy
- Analyst Count
- LNN 1
- VRDN 11
- Target Price
- LNN $136.00
- VRDN $38.80
- AVG Volume (30 Days)
- LNN 85.9K
- VRDN 772.7K
- Earning Date
- LNN 10-23-2025
- VRDN 11-11-2025
- Dividend Yield
- LNN 1.03%
- VRDN N/A
- EPS Growth
- LNN 5.71
- VRDN N/A
- EPS
- LNN 6.96
- VRDN N/A
- Revenue
- LNN $677,807,000.00
- VRDN $305,000.00
- Revenue This Year
- LNN $13.09
- VRDN N/A
- Revenue Next Year
- LNN N/A
- VRDN $34,076.08
- P/E Ratio
- LNN $20.07
- VRDN N/A
- Revenue Growth
- LNN 9.46
- VRDN 5.90
- 52 Week Low
- LNN $112.14
- VRDN $9.90
- 52 Week High
- LNN $150.96
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LNN 55.13
- VRDN 57.62
- Support Level
- LNN $136.71
- VRDN $17.91
- Resistance Level
- LNN $142.50
- VRDN $20.51
- Average True Range (ATR)
- LNN 2.74
- VRDN 0.95
- MACD
- LNN 0.16
- VRDN -0.09
- Stochastic Oscillator
- LNN 80.00
- VRDN 65.77
About LNN Lindsay Corporation
Lindsay Corp provides various proprietary water management and road infrastructure products and services. It has operations categorized into two main reporting segments: Irrigation, and Infrastructure. The company generates maximum revenue from the Irrigation segment. Its Irrigation segment includes manufacturing and marketing center pivot, lateral move, and hose reel irrigation systems, as well as various technology solutions such as GPS positioning and guidance, variable rate irrigation, wireless irrigation management, M2M communication technology, and smartphone applications. Geographically, it derives a majority of its revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).